Chapter title |
Chemotherapy for Melanoma
|
---|---|
Chapter number | 8 |
Book title |
Melanoma
|
Published in |
Cancer treatment and research, January 2016
|
DOI | 10.1007/978-3-319-22539-5_8 |
Pubmed ID | |
Book ISBNs |
978-3-31-922538-8, 978-3-31-922539-5
|
Authors |
Melissa A. Wilson, Lynn M. Schuchter |
Abstract |
Prior to the recent therapeutic advances, chemotherapy was the mainstay of treatment options for advanced-stage melanoma. A number of studies have investigated various chemotherapy combinations in order to expand on the clinical responses achieved with single-agent dacarbazine, but these have not demonstrated an improvement in overall survival. Similar objective responses were observed with the combination of carboplatin and paclitaxel as were seen with single-agent dacarbazine. The combination of chemotherapy and immunotherapy, known as biochemotherapy, has shown high clinical responses; however, biochemotherapy has not been shown to improve overall survival and resulted in increased toxicities. In contrast, palliation and long-term responses have been observed with localized treatment with isolated limb perfusion or infusion in limb-isolated disease. Although new, improved therapeutic options exist for first-line management of advanced-stage melanoma, chemotherapy may still be important in the palliative treatment of refractory, progressive, and relapsed melanoma. We review the various chemotherapy options available for use in the treatment and palliation of advanced-stage melanoma, discuss the important clinical trials supporting the treatment recommendations, and focus on the clinical circumstances in which treatment with chemotherapy is useful. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 184 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 40 | 22% |
Student > Bachelor | 27 | 15% |
Student > Master | 22 | 12% |
Student > Doctoral Student | 10 | 5% |
Researcher | 8 | 4% |
Other | 17 | 9% |
Unknown | 60 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 36 | 20% |
Medicine and Dentistry | 26 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 19 | 10% |
Agricultural and Biological Sciences | 10 | 5% |
Immunology and Microbiology | 6 | 3% |
Other | 20 | 11% |
Unknown | 67 | 36% |